– XELSTRYM, the first and only amphetamine patch will be available by prescription in Q1 2023 –MIAMI and JERSEY CITY, N.J., Jan. 10, 2023 /PRNewswire/ -- Noven Pharmaceuticals. Inc., (Noven), a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. focusing on the development of transdermal treatments, announced today that XELSTRYM™ (dextroamphetamine) transdermal system, CII, the first and only FDA-approved amphetamine patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients six years and older, will be available across the U.S. for healthcare professionals to prescribe later in the first quarter of 2023.1 In anticipation of this, Noven will be publicly presenting XELSTRYM in a branded capacity for the first time at the American Professional Society of ADHD and Related Disorders (APSARD) Conference being held January 13-15 in Orlando, Florida.As a Platinum Sponsor of the APSARD Conference, Noven is hosting an industry symposium focusing on ADHD in adults, which will be presented by Greg Mattingly, MD, Associate Clinical Professor, Washington University and President Elect of APSARD. "Noven's involvement to highlight ADHD in adults at this year's conference strikes a particular chord of excitement as we've learned efforts are underway to develop and publish guidelines in 2023 for the diagnosis and treatment of ADHD in adults, which will address this critical need for healthcare providers and patients," said Naruhito Higo, PhD, Chief Executive Officer of Noven Pharmaceuticals